A randomised phase II study of pre-operative or peri-operative docetaxel, oxaliplatin, capecitabine (DOX) regimen in patients with locally advanced resectable gastric cancer STUDIO DI FASE II RANDOMIZZATO CON DOCETAXEL, OXALIPLATINO, CAPECITABINA (DOX) COME TRATTAMENTO PREOPERATORIO O PERIOPERATORIO (PRIMA E DOPO LA GASTRECTOMIA) IN PAZIENTI CON CARCINOMA GASTRICO LOCALMENTE AVANZATO RESECABILE The percentage of patients receiving all the planned chemotherapeutic cycles. La percentuale dei pazienti che hanno ricevuto tutti i cicli di chemioterapia programmati.

• Country None
• organs None
• Specialty None

Receptorial radiotherapy with 177Lu DOTATATE in somatostatine receptors positive tumours, a phase II study. Radioterapia recettoriale con 177Lu-DOTATATE in tumori con recettori positivi per la somatostatina, studio di fase II disease control rate, DCR, defined as the complete response rate plus the partial response rate plus the rate of patients with stable disease for at least 12 months from therapy start controllo ...

• Country None
• organs None
• Specialty None

Phase II Trial of Temozolomide in Patients affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer with MGMT methylation. GOPAV03 Overall response rate [ORR = CR + PR]

• Country None
• organs None
• Specialty None

CLINICAL AND TRASLATIONAL PHASE II STUDY OF LIPOSOMAL DOXORUBICIN PLUS DOCETAXEL AND TRASTUZUMAB WITH METFORMIN AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY ADVANCED HER2 POSITIVE BREAST CANCER. Studio clinico e traslazionale di fase II con Doxorubicina Liposomiale (Myocet) più Docetaxel, Trastuzumab e Metformina come terapia sistemica primaria per il cancro della mammella operabile e localmente avanzato Her-2 positivo To evaluate the pathologic complete response rate (pCR). Valutare il tasso di risposta patologica completa (pCR)

• Country None
• organs None
• Specialty None

Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC. A phase IV study Studio randomizzato cross-over per la valutazione della preferenza dei pazienti per la formulazione orale o endovenosa della Vinorelbina nel trattamento del Carcinoma Polmonare Non a Piccole Cellule (NSCLC) avanzato. Studio randomizzato di fase IV Patient preference for oral or intravenous vinorelbine, from the 3° cycle onwards determinazione della percentuale di pazienti che esprimano la preferenza per la via di somministrazione orale (...

• Country None
• organs None
• Specialty None

Olaparib as salvage treatment for cisplatin-resistant germ cell tumor. Olaparib come trattamento di salvataggio per tumore a cellule germinali cisplatino-resistenti to evaluate the preliminary activity of Olaparib in GCT (Germ Cell Tumors). valutare l'attività di Olaparib nei tumori a cellule germinali.

• Country None
• organs None
• Specialty None

IMMUNOTHERAPY OF MAINTENANCE IN THE PATIENTS WITH METASTATIC MELANOMA, CLINICAL BENEFIT AFTER CHEMOTHERAPY To evaluate if treatment with low dose Interleukin-2 (IL-2), 13-cis Retinoic Acid (RA) and a pegylated form of alfa-Interferon (PEG-IFN) is able to improve the time to progression of patients with met...

• Country None
• organs None
• Specialty None

A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy of pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-positive metastatic breast cancer • Safety of treatment of the combination of DHEA and an aromatase inhibitor (anastrozole or letrozole or exemestane) in pre-treated post-menopausal metastatic breast cancer patients • Efficacy (eval...

• Country None
• organs None
• Specialty None

Phase II comparative study of Myocet plus Cyclophosphamide plus metformin versus Myocet plus Cyclophosphamide in first line treatment of HER2 negative metastatic breast cancer patients The primary objective of this study is to evaluate the efficacy of the combination of Myocet plus Cyclophosphamide plus metformin as compared to Myocet plus Cyclophosphamide in HER2 negative metastat...

• Country None
• organs None
• Specialty None

Receptorial radiotherapy with 177Lu-DOTA-Tyr3-Octreotate as Maintaining Therapy in Extended Small Cell Lung Cancer (SCLC) after a first standard chemotherapy line evaluate the percentage of patients without progression (PFS) at one year from the CT start.

• Country None
• organs None
• Specialty None